

BEST AVAILABLE COPY

Serial No.: 09/091,062
Group Art Unit: 1616

Remarks

Claims 1-17, 20-43, 45-48, and 50-53 are pending in this application. Claims 1, 26, 27, 28, 30, and 50 have been amended to more clearly define the invention. Claims 1-17, 19-23, 25-48, and 50-53 stand rejected.

Priority

The Examiner has objected to the priority claim of the instant invention. Applicants respectfully traverse this objection. The filing date of the early application is not at issue with regard to any intervening references there is no need for the Examiner to make a determination as to whether the requirements of 35 U.S.C. 120 have been met.

Claim Rejections under 35 U.S.C. §112, Second Paragraph

Claims 1-17, 19-23, 25-48, and 50-53 stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly failing to meet the enablement requirement.

The Office Action states that "an effective dose of a sexual dysfunctional active agent" is not enabled to the extent that this term encompasses compounds other than sildenafil.

Applicants respectfully disagree. However, without conceding the correctness of the rejection, Applicants have amended the claims to recite "sildenafil citrate." It is submitted that the claims as amended are fully enabled. Reconsideration and withdrawal of the rejection are respectfully requested.

Serial No.: 09/091,062
Group Art Unit: 1616

BEST AVAILABLE COPY


CONCLUSION

As all of the outstanding rejections have been addressed and all of the claims are believed to be in condition for allowance, the Applicants respectfully request a Notice of Allowability. The Examiner is invited to contact the undersigned representative should any further issues arise.

Respectfully submitted,

DECHERT LLP

Date: 28 Jan '05


John W. Ryan
Reg. No. 33,771

Thomas M. Haas
Reg. No. 50,210

Dechert LLP
1775 I Street, N.W.
Washington, D.C. 20006
Telephone (202) 261-3375
Fax (202) 261-3333